Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130938 | 0.84 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL2714710 | 0.80 | SLC6A2 (0.52) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10130882 | 0.78 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10132280 | 0.78 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10130888 | 0.78 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10130891 | 0.78 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10130934 | 0.78 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10130838 | 0.77 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL10130840 | 0.77 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 | |
| SCHEMBL9951487 | 0.77 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| US-8906913-B2 | Azabicyclohexanes | PANACEA BIOTEC LIMITED (IN) | 2014-12-09 | — | — | US | disclosed |
| EP-2445887-B1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD (IN) | 2014-11-05 | — | — | EP | disclosed |
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
| WO-2010150281-A2 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | SLC6A2 467/4885SLC6A4 544/4885SLC6A3 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.